QUINAZOLINE DERIVATIVES
    3.
    发明申请
    QUINAZOLINE DERIVATIVES 审中-公开
    喹诺酮衍生物

    公开(公告)号:US20120329795A1

    公开(公告)日:2012-12-27

    申请号:US13607999

    申请日:2012-09-10

    CPC分类号: C04B35/632 C07D401/12

    摘要: The invention concerns quinazoline derivatives of Formula I: wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.

    摘要翻译: 本发明涉及式I的喹唑啉衍生物:其中R1,X1,R2,R3,R5,n和m各自具有本说明书中定义的任何含义; 其制备方法,含有它们的药物组合物及其在制备用于预防或治疗对EGF和erbB受体酪氨酸激酶的抑制敏感的肿瘤中作为抗增殖剂的药物中的用途。

    Estrogen receptor-&bgr; ligands
    8.
    发明授权
    Estrogen receptor-&bgr; ligands 失效
    雌激素受体-β配体

    公开(公告)号:US06518301B1

    公开(公告)日:2003-02-11

    申请号:US09959032

    申请日:2002-01-07

    IPC分类号: A61K3138

    摘要: A method for treating a disease associated with the estrogen receptor-&bgr;, comprising the step of administering a therapeutically-effective amount of a compound that satisfies the equation: (Ki&agr;A/Ki&bgr;A)/(Ki&agr;E/Ki&bgr;E)>1, optionally having the general structure (I).

    摘要翻译: 一种用于治疗与雌激素受体-β相关的疾病的方法,包括施用治疗有效量的满足以下等式的化合物的步骤:(KialphaA / KibetaA)/(KialphaE / KibetaE)> 1,任选地具有一般 结构(I)。